DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis
Metrics: PDF 2193 views | HTML 1928 views | ?
Hyeong Sim Choi1, Kangwook Lee1, Min Kyoung Kim1, Kang Min Lee1, Yong Cheol Shin2, Sung-Gook Cho3, Seong-Gyu Ko2
1Department of Science in Korean Medicine, Graduate School, Kyung Hee University, 1 Hoegi, Seoul 130-701, Korea
2Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 1 Hoegi, Seoul 130-701, Korea
3Department of Biotechnology, Korea National University of Transportation, Jeungpyeong, Chungbuk 368-701, Korea
Sung-Gook Cho, e-mail: [email protected]
Seong-Gyu Ko, e-mail: [email protected]
Keywords: DSGOST, angiogenesis, tumor, VEGF, herbal medicine
Received: August 06, 2015 Accepted: February 16, 2016 Published: March 08, 2016
Tumor growth requires a process called angiogenesis, a new blood vessel formation from pre-existing vessels, as newly formed vessels provide tumor cells with oxygen and nutrition. Danggui-Sayuk-Ga-Osuyu-Saenggang-Tang (DSGOST), one of traditional Chinese medicines, has been widely used in treatment of vessel diseases including Raynaud’s syndrome in Northeast Asian countries including China, Japan and Korea. Therefore, we hypothesized that DSGOST might inhibit tumor growth by targeting newly formed vessels on the basis of its historical prescription. Here, we demonstrate that DSGOST inhibits tumor growth by inhibiting VEGF-induced angiogenesis. DSGOST inhibited VEGF-induced angiogenic abilities of endothelial cells in vitro and in vivo, which resulted from its inhibition of VEGF/VEGFR2 interaction. Furthermore, DSGOST attenuated pancreatic tumor growth in vivo by reducing angiogenic vessel numbers, while not affecting pancreatic tumor cell viability. Thus, our data conclude that DSGOST inhibits VEGF-induced tumor angiogenesis, suggesting a new indication for DSGOST in treatment of cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.